Research Analysts Offer Predictions for OLMA FY2025 Earnings

by · The Markets Daily

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) – Investment analysts at HC Wainwright boosted their FY2025 earnings estimates for shares of Olema Pharmaceuticals in a report released on Thursday, December 11th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.87) per share for the year, up from their previous forecast of ($1.91). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($2.33) EPS, FY2027 earnings at ($2.41) EPS, FY2028 earnings at ($2.04) EPS and FY2029 earnings at ($1.53) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05).

Other equities analysts have also recently issued reports about the company. Guggenheim initiated coverage on Olema Pharmaceuticals in a report on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price objective for the company. Zacks Research upgraded Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. Citigroup upped their price objective on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. The Goldman Sachs Group increased their price objective on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.50.

Read Our Latest Analysis on Olema Pharmaceuticals

Olema Pharmaceuticals Trading Down 4.3%

Shares of OLMA stock opened at $34.28 on Monday. The stock has a market cap of $2.35 billion, a P/E ratio of -18.33 and a beta of 1.87. Olema Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $36.26. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $16.71 and a 200 day simple moving average of $9.68.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently made changes to their positions in OLMA. Ameritas Investment Partners Inc. increased its position in Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after purchasing an additional 2,168 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Olema Pharmaceuticals by 602.9% in the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after buying an additional 5,866 shares in the last quarter. FNY Investment Advisers LLC grew its stake in shares of Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after buying an additional 5,000 shares during the last quarter. Quarry LP acquired a new position in shares of Olema Pharmaceuticals during the first quarter worth $45,000. Finally, Alpine Global Management LLC acquired a new position in shares of Olema Pharmaceuticals during the first quarter worth $52,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $8.33, for a total transaction of $83,300.00. Following the completion of the transaction, the director owned 744,140 shares of the company’s stock, valued at approximately $6,198,686.20. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.36% of the stock is currently owned by corporate insiders.

Olema Pharmaceuticals Company Profile

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

Further Reading